PMID- 29805657
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 6
DP  - 2018 Jun
TI  - Clinicopathological analysis of epithelioid inflammatory myofibroblastic sarcoma.
PG  - 9317-9326
LID - 10.3892/ol.2018.8530 [doi]
AB  - Inflammatory myofibroblastic tumor (IMT) is a distinctive neoplasm composed of 
      myofibroblastic and fibroblastic spindle cells, accompanied by the inflammatory 
      infiltration of plasma cells, lymphocytes and/or eosinophils. Epithelioid 
      inflammatory myofibroblastic sarcoma (EIMS), which primarily consists of cells 
      with a round or epithelioid morphology, is associated with a poor prognosis and 
      rapid development of local recurrence, and has been recognized to be a variant of 
      IMT. Diagnosis of EIMS is difficult owing to its close resemblance to malignant 
      mesothelioma, anaplastic large cell lymphoma, gastrointestinal stromal tumor and 
      other malignant diseases. In the present study, a case of this rare tumor was 
      evaluated in a 26-year-old male who was admitted to hospital after experiencing 
      abdominal pain for ~18 days and abdominal distention for 1 week. The patient's 
      tumor was examined by imaging, gross examination, histology, immunohistochemistry 
      and fluorescence in situ hybridization (FISH). The magnetic resonance imaging 
      enhanced-scanning image revealed that the morphology of the tumor was irregular, 
      and signal was medley consisting of high and low hybrid reinforcement. Tumors 
      were located in the bladder and rectal pit, in the lower part of the lower 
      abdomen, indicating the presence of malignancy and involvement of the small 
      intestine and rectum. Enhanced-scanning imaging revealed notable inhomogeneous 
      enhancement. Gross examination revealed that the tumor was solid and had a 
      variegated appearance with alternating fleshy and mucoid areas in the cut 
      surface. Microscopically, the tumors were dominated by sheets of 
      epithelioid-to-round cells with a prominent inflammatory infiltrate. The majority 
      of the stroma was myxoid. Immunohistochemically, the tumor cells exhibited 
      diffuse strong staining for ALK receptor tyrosine kinase (hereafter ALK), 
      vimentin, tumor protein P53, desmin, Wilms' tumor 1 and programmed death-ligand 
      1. FISH analysis also revealed the existence of ALK rearrangement. The expression 
      of PD-L1 in EIMS indicates that the immune checkpoint blockade could represent a 
      novel therapy for the treatment of EIMS.
FAU - Du, Xuemei
AU  - Du X
AD  - Department of Pathology, Capital Medical University Affiliated Beijing Shijitan 
      Hospital, Beijing 100038, P.R. China.
FAU - Gao, Ying
AU  - Gao Y
AD  - Department of Pathology, Capital Medical University Affiliated Beijing Shijitan 
      Hospital, Beijing 100038, P.R. China.
FAU - Zhao, Hongyu
AU  - Zhao H
AD  - Department of Pathology, Capital Medical University Affiliated Beijing Shijitan 
      Hospital, Beijing 100038, P.R. China.
FAU - Li, Bin
AU  - Li B
AD  - Department of Nuclear Magnetic Resonance, Capital Medical University Affiliated 
      Beijing Shijitan Hospital, Beijing 100038, P.R. China.
FAU - Xue, Weimin
AU  - Xue W
AD  - Cyttel Biosciences Inc., Beijing 101111, P.R. China.
FAU - Wang, Daye
AU  - Wang D
AD  - Department of Pathology, Basic Medical College, Capital Medical University, 
      Beijing 100069, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180418
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5958778
OTO - NOTNLM
OT  - epithelioid inflammatory myofibroblastic sarcoma
OT  - immunohistochemistry
OT  - programmed cell-death ligand 1
OT  - therapy
EDAT- 2018/05/29 06:00
MHDA- 2018/05/29 06:01
PMCR- 2018/04/18
CRDT- 2018/05/29 06:00
PHST- 2017/05/19 00:00 [received]
PHST- 2018/02/12 00:00 [accepted]
PHST- 2018/05/29 06:00 [entrez]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2018/05/29 06:01 [medline]
PHST- 2018/04/18 00:00 [pmc-release]
AID - OL-0-0-8530 [pii]
AID - 10.3892/ol.2018.8530 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Jun;15(6):9317-9326. doi: 10.3892/ol.2018.8530. Epub 2018 Apr 
      18.